Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

697
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
697
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

908
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
908
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

133
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
133
Cancer Therapies02:49

Cancer Therapies

9.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tailoring Avidity through Morphology: Structure-Avidity Relationship in CD38-Binding Nanofiber Radiotracers.

ACS applied bio materials·2026
Same author

Reply by Authors.

The Journal of urology·2026
Same author

CD8 PET imaging with [<sup>89</sup>Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study.

Journal for immunotherapy of cancer·2026
Same author

ACR Appropriateness Criteria® Penetrating Trauma-Abdomen and Pelvis: Update 2026.

Journal of the American College of Radiology : JACR·2026
Same author

ACR Appropriateness Criteria® Suspected and Known Renal or Splanchnic Artery Aneurysm.

Journal of the American College of Radiology : JACR·2026
Same author

ACR Appropriateness Criteria® Staging and Follow-up of Gastric Cancer.

Journal of the American College of Radiology : JACR·2026

Related Experiment Video

Updated: Nov 28, 2025

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

8.5K

Novel Agents and Future Perspectives on Theranostics.

Lilja B Solnes1, Monica Shokeen2, Neeta Pandit-Taskar3

  • 1The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD.

Seminars in Radiation Oncology
|November 28, 2020
PubMed
Summary
This summary is machine-generated.

Precision medicine is driving interest in radiopharmaceutical therapy and theranostics. Emerging alpha emitters offer targeted cancer treatment with potentially lower toxicity compared to beta emitters.

More Related Videos

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
08:09

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy

Published on: April 6, 2015

11.9K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K

Related Experiment Videos

Last Updated: Nov 28, 2025

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

8.5K
Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
08:09

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy

Published on: April 6, 2015

11.9K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Precision medicine and theranostics are gaining traction in cancer treatment.
  • FDA approvals for somatostatin receptor and 131I-MIBG therapies highlight progress.
  • Advancements in targeted therapies, including PSMA-directed treatments for prostate cancer, are transforming clinical practice.

Purpose of the Study:

  • To review the current landscape of radiopharmaceutical therapy and theranostics.
  • To explore novel radiopharmaceutical agents and strategies in development.
  • To discuss the emerging role and potential advantages of alpha emitters in targeted radiotherapy.

Main Methods:

  • Literature review of recent advancements in radiopharmaceutical therapy.
  • Analysis of FDA-approved therapies and ongoing clinical trials.
  • Comparison of beta and alpha emitter characteristics for targeted radiotherapy.

Main Results:

  • Significant clinical impact from approved somatostatin receptor and 131I-MIBG therapies.
  • Rapid development of novel agents, including peptide ligands and antibody-based therapeutics.
  • Growing interest in alpha emitters due to their high-energy ionization and localized tissue effects.

Conclusions:

  • Radiopharmaceutical therapy and theranostics are pivotal in precision medicine.
  • Novel radiopharmaceutical agents are advancing preclinical and clinical development.
  • Alpha emitters represent a promising frontier in targeted radiotherapy, offering enhanced efficacy and reduced normal tissue toxicity.